

07 **PhD
Days**
Oct 2021
Thursday

WEBINAR

via Webex*

45' (talk) + 30' (discussion)

11.00am - 12.15pm



Role of mRNA Translation in Melanoma Biology and Therapeutics

ABSTRACT

Therapeutic progress in metastatic melanoma have been the fastest among all cancers in the last ten years thanks to the demonstration of efficacy of immunotherapy targeting immune checkpoints CTLA-4 and PD1. The median survival of patients has more than doubled and some patients are definitely cured. These new strategy has quickly gone beyond the field of melanoma and is now used successfully against many other cancers. However, these revolutionary treatments are not effective in every patients, and resistance appears either immediately (i.e. primary resistance) or after an initial benefit of the treatment (secondary resistance).

Many of these resistance mechanisms, genetic or epigenetic, have been described, but they are far from being fully elucidated. Our main challenges today are to unravel these resistance mechanisms in order delay or circumvent them. We demonstrated that the protein complex involved in the control of translation initiation, eIF4F, plays a critical part in resistance to targeted agent as well as in PDL1 expression. We have continued to explore the relationship between the control of protein translation and immunoreceptor expression. Our recent data shows that additional immunoreceptors are also controlled by eIF4F and could be targeted by inhibitors of this complex. Our goal is to unravel the dynamics of immunoreceptors mRNAs translation, both on cancer cells and on cells of the microenvironment, during the course of the immune response using mice models and sequential biopsies of patients treated with immune checkpoint inhibitors. These results offer promising perspectives for the identification of biomarkers of efficacy and resistance as well as for the development of new therapeutic strategies based on translation inhibitors in combination with standard cancer treatments



SPEAKER

Prof Caroline Robert

Head of the Dermatology Unit at Gustave Roussy,
Co-director of the Melanoma Research Unit at
INSERM 981 Paris-Sud University

HOST:

Department of Oncology (LIH)

RESPONSIBLE LIH SCIENTIST:

Bassam Janji / (bassam.janji@lih.lu)

www.lih.lu
www.uni.lu

Supported by:



***To join the Webinar:**

JOIN

Event number: **174 600 1392**

Event password: **dMMwp8NB4M5**



PROGRAMME